AZD0120 / AstraZeneca - LARVOL DELTA

One-year follow-up of CD19/BCMA dual-targeting fastcar-T GC012F (AZD0120) therapy in patients with refractory systemic lupus erythematosus (ASH 2025) - P1/2 | "Patients not in remission still hadimproved disease activity. An ongoing phase 1/2 trial (NCT06530849) is further evaluating its safety andefficacy in a larger cohort."

Clinical • Glomerulonephritis • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Rheumatology • Systemic Lupus Erythematosus

ZENITH: An Open-label Study of AZD0120 in Adults With Multiple Sclerosis (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: AstraZeneca

New P1 trial • CNS Disorders • Multiple Sclerosis

A dual targeting BCMA and CD19 fastcar-t (GC012F/AZD0120) as first-line therapy for newly diagnosed multiple myeloma (ASH 2025) - P1, P1/2 | "Here, we report the combined data of these twostudies to provide long term follow up data of GC012F/AZD0120 in NDMM pts.Methods Eligible NDMM pts received a single infusion of GC012F/AZD0120 following two cycles lenalidomide,bortezomib and dexamethasone (RVd) induction therapy...GC012F/AZD0120 was administered at 4 dose levels:1x105/kg (n=1), 1.5x105/kg (n=3), 2x105/kg (n=4), or 3x105/kg (n=22) after a standard 3-daylymphodepletion regimen of fludarabine and cyclophosphamide...3 pts were treated with one dose of tocilizumab and 1 pt was treated with one dose oftocilizumab and corticosteroids...These promising results highlight the potential ofGC012F/AZD0120 CAR-T therapy for treating NDMM patients with HR features and transplant ineligibleNDMM pts. Further research with a larger patient population and extended follow-up is needed tovalidate these findings and address this critically unmet medical need."

Clinical • Hematological Malignancies • Inflammation • Multiple Myeloma • Plasmacytoma • PLAAT3

CD19/BCMA Dual-Targeting FasTCAR-T Cells GC012F (AZD0120) in patients with refractory Systemic Lupus Erythematosusm: an open-label, single-center Phase I study (ACR Convergence 2025) - P1, P1/2 | "All patients received a single infusion of autologous CD19-BCMA dual chimeric antigen receptor (CAR) T cells at one of three different dose levels following preconditioning with fludarabine and cyclophosphamide. GC012F CAR-T cell therapy was well tolerated and demonstrated high efficacy in patients with refractory SLE. A multicenter phase1/2 study (NCT06530849) is ongoing to further evaluate the safety and efficacy of GC012F in a broader range of patients with SLE."

CAR T-Cell Therapy • Clinical • P1 data • Fibrosis • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Lupus • Renal Disease • Systemic Lupus Erythematosus

Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma: Preliminary Results from the DURGA-1 Phase 1b/2 study (ASH 2025) - P1/2 | "Whileadvances such as BCMA-directed CAR T-cell therapy have improved outcomes, challenges persist,including disease relapse, treatment toxicities (CRS, ICANS, and non-ICANS neurotoxicities), and access.AZD0120 (formerly GC012F) is a first-in-class autologous BCMA/CD19 dual-targeting CAR T-cell therapyusing the FasTCAR rapid manufacturing platform that preserves the naive and central memory T-cellphenotypes with marked in vivo proliferative capacity...The median age was 64 y (range 44–78), median pLOT was 4 (range 3–7), 72% were triple-classrefractory, 20% had prior BCMA CAR T-cell therapy, 4% had prior teclistamab, 28% had high-riskcytogenetic features [del(13q), del(17p13), t(4; 14), t(14; 16), amp(1q)], and 8% had extramedullaryplasmacytomas...Median timeto CRS onset (DL1/DL2) was 9 d (range 2–11), with a median duration of 2 d (range 1–4); 12 pts (48%)received tocilizumab for CRS management and 12% received dexamethasone... Preliminary phase 1b results..."

CAR T-Cell Therapy • Clinical • P1/2 data • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Immunology • Multiple Myeloma • Plasmacytoma

GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103) (clinicaltrials.gov) - P1 | N=6 | Recruiting | Sponsor: Daishi Tian | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Myasthenia Gravis

GC012F Injection in Refractory Idiopathic Inflammatory Myopathy (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Daishi Tian

New P1 trial • Myositis

GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103) (clinicaltrials.gov) - P1 | N=6 | Not yet recruiting | Sponsor: Daishi Tian

New P1 trial • CNS Disorders • Myasthenia Gravis

ALACRITY: A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis. (clinicaltrials.gov) - P1/2 | N=91 | Recruiting | Sponsor: Alexion Pharmaceuticals, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Amyloidosis

ALACRITY: A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis (clinicaltrials.gov) - P1/2 | N=91 | Not yet recruiting | Sponsor: Alexion Pharmaceuticals, Inc.

New P1/2 trial • Amyloidosis

GC012F in Patients With Autoimmune Diseases (clinicaltrials.gov) - P1 | N=15 | Not yet recruiting | Sponsor: Qiong Fu

New P1 trial • Immunology • Myositis • Scleroderma • Systemic Sclerosis

DURGA-3: A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=110 | Recruiting | Sponsor: Gracell Biotechnologies (Shanghai) Co., Ltd. | Trial completion date: Jun 2026 ➔ Mar 2026

Trial completion date • Hematological Malignancies • Multiple Myeloma • Oncology

A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Early-Line Treatment in Subjects With Multiple Myeloma (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: AstraZeneca

New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology

An Exploratory Clinical Study of GC012F Injection for Refractory gMG (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: Zhejiang University | N=18 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • CNS Disorders • Myasthenia Gravis

UPDATED RESULTS OF A PHASE I OPEN-LABEL SINGLE-ARM STUDY OF DUAL TARGETING BCMA AND CD19 FASTCAR-T (GC012F/AZD0120) AS FIRST-LINE THERAPY FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED HIGH-RISK MULTIPLE MYELOMA (EHA 2025) - P1/2 | "TE NDMM patients aged 18 to 70 were eligible if they had at least one of the following high risk features: R-ISS stage II or III; del (17p), t (4; 14), t (14; 16), or ≥ 4 copies of 1q21; extramedullary disease (EMD); IgD or IgE subtype; LDH levels above the upper limit of normal; any of the HR criterion defined by mSMART3.0.GC012F/AZD0120 was administered as a single infusion at 3 dose levels: 1x105/kg (n=1), 2x105/kg (n=4), or 3x105/kg (n=17), following a standard 3-day lymphodepletion regimen of fludarabine and cyclophosphamide.A total of 22 patients with a median age of 59 years old were enrolled and evaluable...Two pts received tocilizumab and 1 pt received tocilizumab and corticosteroid... Consistent with findings from the previous relapsed/ refractory MM cohort treated with GC012F/AZD0120, initial data from this study demonstrates that GC012F/AZD0120 induced deep and durable responses in TE HR NDMM pts, with a highly favorable safety profile. All patients..."

Clinical • P1 data • Hematological Malignancies • Inflammation • Multiple Myeloma • Oncology • Transplantation

AUTOLOGOUS B CELL MATURATION ANTIGEN (BCMA) AND CD19 DUAL TARGETING FASTCAR-T CELLS (GC012F/AZD0120) AS FIRST-LINE THERAPY FOR ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS (EHA 2025) - P1, P1/2 | "After enrollment, patients were permitted to receive up to two cycles of bortezomib, lenalidomide and dexamethasone (VRd) induction therapy before or after apheresis, at the discretion of investigators...All pts recovered from CRS within 5 days and only 1 pt received tocilizumab... GC012F/AZD0120 exhibited a high clinical efficacy, and a favorable safety profile in this study of patients aged > 70. Given these excellent efficacy and safety data, chronological age should not be used as a criterion to exclude patients from CAR T cell clinical trials or from receiving anti-BCMA CAR T-cell therapy in a real-world setting. Future studies with larger cohorts are needed to confirm this approach as a standard of care."

CAR T-Cell Therapy • Clinical • Geriatric Disorders • Hematological Malignancies • Inflammation • Multiple Myeloma • Oncology

FIRST-IN-HUMAN STUDY OF CD19/BCMA DUAL-TARGETING FASTCAR-T GC012F (AZD0120) FOR PATIENTS WITH REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS (EHA 2025) - P1, P1/2 | "Lymphodepletion was achieved using fludarabine (30 mg/m²/day on days -5 to -3) and cyclophosphamide (1000 mg/m²/day on day -3), followed by GC012F infusion on day 0 in three escalating dose groups (1, 2, and 3 ×10⁵ CAR+ T cells/kg)...One patient had Grade 2 ICANS at Day 7, resolved with dexamethasone and levetiracetam... Preliminary results suggest that GC012F, a CD19/BCMA dual-targeting CAR-T therapy, has a favorable early safety profile and promising efficacy in rSLE patients. A Phase 1/2 study (NCT06530849) is ongoing to further evaluate its safety and efficacy."

Clinical • P1 data • Glomerulonephritis • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Systemic Lupus Erythematosus

Preliminary results of CD19/BCMA Dual-Targeting FasTCAR-T Cells GC012F (AZD0120) in patients with refractory Systemic Lupus Erythematosus-an open-label, single-arm study (EULAR 2025) - P1, P1/2 | "Standard lymphodepleting regimen (fludarabine 25 mg/m^2/day and cyclophosphamide 250 mg/m^2/day for 3 days, Day -5 to -3) was given before CAR-T cell infusion...The Grade 2 CRS event was observed at dose of 3×10 5 CAR-T cells/kg, with onset on day 7 and resolved on day 8 after treatment with dexamethasone and tocilizumab...At month 9, out of 10 patients, 7 patients stopped glucocorticoids and 4 of them also discontinued hydroxychloroquine, the other 3 patients were treated with prednisone 5mg/day... GC012F, a CD19/BCMA dual-targeting CAR-T, induced disease remission in refractory SLE patients with early favorable safety profile. A multicenter phase1/2 study (NCT06530849) is ongoing to further evaluate the safety and efficacy of GC012F in a broader range of patients with SLE."

CAR T-Cell Therapy • Clinical • Glomerulonephritis • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Otorhinolaryngology • Pneumonia • Renal Disease • Respiratory Diseases • Systemic Lupus Erythematosus

A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE (clinicaltrials.gov) - P1/2 | N=150 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=80 | Recruiting | Sponsor: AstraZeneca | Trial primary completion date: Apr 2027 ➔ Aug 2027

Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE (clinicaltrials.gov) - P1/2 | N=150 | Not yet recruiting | Sponsor: AstraZeneca

New P1/2 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=80 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Jun 2028 ➔ Sep 2028 | Trial primary completion date: Dec 2026 ➔ Apr 2027

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

KY2024-853: An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: Chongbo Zhao

New P1 trial • CNS Disorders • Myasthenia Gravis

Autologous B Cell Maturation Antigen (BCMA) and CD19 Dual Targeting Fastcar-T Cells (GC012F/AZD0120) As First-Line Therapy for Elderly Patients with Newly Diagnosed Multiple Myeloma Patients (ASH 2024) - P1, P1/2 | "After enrollment, patients were permitted to receive up to two cycles of bortezomib, lenalidomide and dexamethasone (VRd) induction therapy before or after apheresis, at the discretion of investigators...All pts recovered from CRS within 5 days and only 1 pt received tocilizumab...Conclusion Consistent with the data from previous RRMM and transplant-eligible NDMM studies of GC012F, data from this study demonstrate that GC012F/AZD0120 resulted in a very favorable safety profile and promising, deep responses in elderly NDMM pts. Our results suggest that age alone should not preclude patients from receiving highly effective treatments aimed at cure or long-term disease control."

CAR T-Cell Therapy • Clinical • Hematological Malignancies • Inflammation • Multiple Myeloma • Oncology

AstraZeneca showcases strength of haematology portfolio and pipeline at ASH 2024 (AstraZeneca Press Release) - P1/2 | N=20 | NCT04935580 | Sponsor: Shanghai Changzheng Hospital | "Early data for AZD0120 (GC012F)...will show potential as a first-line therapy for elderly patients with newly diagnosed transplant ineligible MM. Preliminary results from the ongoing investigator-initiated trial of AZD0120 suggest deep responses and an acceptable safety profile, with no ICANS and no ≥Grade 2 CRS events observed in this patient population. An oral presentation will share preclinical data demonstrating the anti-tumour activity of AZD5492, a next-generation CD8 selective, CD20-targeting T-cell engager, designed using AstraZeneca’s innovative Target Induced T-cell Activating Nanobody (TITAN) platform."

P1/2 data • Preclinical • Multiple Myeloma • Oncology